Ruplizumab (trade name Antova) is a humanized monoclonal antibody intended for the treatment of rheumatic diseases like systemic lupus erythematosus and lupus nephritis. A study showed that the drug was associated with life-threatening thromboembolisms, while another study only found thrombocytopenia.
Property | Value |
---|---|
dbo:abstract |
|
dbo:alternativeName |
|
dbo:casNumber |
|
dbo:fdaUniiCode |
|
dbo:wikiPageID |
|
dbo:wikiPageLength |
|
dbo:wikiPageRevisionID |
|
dbo:wikiPageWikiLink | |
dbp:atcPrefix |
|
dbp:casNumber |
|
dbp:chemspiderid |
|
dbp:mabType |
|
dbp:source |
|
dbp:target | |
dbp:tradename |
|
dbp:type |
|
dbp:unii |
|
dbp:verifiedfields |
|
dbp:verifiedrevid |
|
dbp:wikiPageUsesTemplate | |
dct:subject | |
gold:hypernym | |
rdf:type |
|
rdfs:comment |
|
rdfs:label |
|
owl:sameAs | |
prov:wasDerivedFrom | |
foaf:isPrimaryTopicOf | |
is dbo:wikiPageWikiLink of | |
is foaf:primaryTopic of |